Video Experimental Relacionado

Updated: Jul 31, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

Un péptido sintético que es un antagonista del receptor de bombesina

R T Jensen, S W Jones, K Folkers

|May 3, 1984

Resumen

Se ha identificado un nuevo antagonista del receptor de bombesina, un péptido de sustancia P modificado. Este descubrimiento ayuda a entender las bombas en las bombas.

Área de la Ciencia:

Ciencia de los péptidos Ciencia de los péptidos
La neuroendocrinología en neuroendocrinología.
Gastroenterología y Gastroenterología.

Sus antecedentes:

Bombesin, un tetradecapéptido de la piel de la rana, y sus análogos se encuentran en los sistemas de los mamíferos.
Estos péptidos exhiben efectos farmacológicos significativos en el sistema nervioso central y el músculo liso.
Los receptores de bombesina están presentes en las células acinares pancreáticas, el cerebro y las células pituitarias, pero faltan antagonistas.

Objetivo del estudio:

Identificar un antagonista del receptor de bombesina para facilitar los estudios sobre las funciones fisiológicas de la bombesina.
Para caracterizar las propiedades antagónicas de una sustancia P análoga contra los receptores de bombesin.

Principales métodos:

Utilizó un péptido de sustancia P modificado, [D-Arg, D-Pro, D-Trp, Leu] sustancia P, como un antagonista potencial.
Evaluó la capacidad del péptido para inhibir la secreción de enzimas estimuladas por bombas de la acini pancreática dispersa.
Inhibición evaluada de otros péptidos que interactúan con el receptor de bombesina.

Principales resultados:

El análogo de la sustancia P inhibió competitivamente la secreción enzimática inducida por bombas.
Este péptido también antagonizó las acciones de otros ligandos del receptor de la bombesina.
Demostró la utilidad de este péptido como un antagonista del receptor de la bombesina.

Conclusiones:

Se ha identificado y caracterizado un nuevo antagonista del receptor de bombesina.
Este antagonista es un péptido de sustancia P modificado, [D-Arg, D-Pro, D-Trp, Leu] sustancia P.
Este hallazgo proporciona una herramienta crucial para investigar el significado fisiológico de las bombas.

Más Videos Relacionados

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Videos de Conceptos Relacionados

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...